Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 11/20 | 0.65 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | ACLY | P53396 | 1/20 | 0.48 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15045825 | 0.86 | MTNR1A (0.50) | MTNR1ATP53ACLYMALT1HDAC1 | |
| SCHEMBL5344278 | 0.82 | MTNR1A (0.72) | MTNR1AMTNR1BACLY | |
| SCHEMBL7281450 | 0.81 | MTNR1A (0.68) | MTNR1AMTNR1B | |
| SCHEMBL6076652 | 0.81 | MTNR1A (0.70) | MTNR1AMTNR1BMALT1 | |
| SCHEMBL5334595 | 0.81 | MTNR1A (0.70) | MTNR1AMTNR1BTP53ACLY | |
| SCHEMBL5346519 | 0.81 | MTNR1A (0.70) | MTNR1AMTNR1BACLYMALT1 | |
| SCHEMBL5346165 | 0.81 | MTNR1A (0.70) | MTNR1AMTNR1BTP53HDAC1 | |
| SCHEMBL5261920 | 0.79 | MTNR1A (1.00) | MTNR1AMTNR1BTP53 | |
| SCHEMBL7201059 | 0.78 | MTNR1A (0.62) | MTNR1AMTNR1B | |
| SCHEMBL9692800 | 0.78 | MALT1 (0.53) | MTNR1ATP53ACLYMALT1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | MTNR1A 710/4885MTNR1B 427/4885TP53 1133/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | MTNR1A 710/4885MTNR1B 427/4885TP53 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.